Marijuana is one of the most common illicit drugs used by patients with schizophrenia. Recent research into marijuana’s adverse role for people dealing with psychosis and schizophrenia is concerning. The author, Dr. Brian Miller (MD, PhD, MPH), has complied a series of research studies and their key findings that outline the[Read More…]
Author: admin
Drug-Free Communities Program, A National Evaluation
Marijuana still remains of concern when addressing youth use, access and health impacts. To help bridge that gap the Drug-Free Communities (DFC) program, a federally funded drug prevention and education program since 1997, focuses on reducing substance use in both youths and adults. The DFC program just released their annual[Read More…]
Illicit Marijuana Disguised as Hemp
With the passage of the Agriculture Improvement Act of 2018, also known as the “2018 Farm Bill”, hemp (part of the Cannabis Sativa L. plant) became a legal agricultural commodity. The caveat to this designation is that hemp, by definition, is to have a potency level of Delta-9 Tetrahydrocannabinol (THC) of[Read More…]
CADCA’s Practical Theorist 12: Cannabis, The Current State of Affairs
The Community Anti-Drug Coalitions of America (CADCA) has just issued the twelfth edition in their ongoing educational “Practical Theorist” series. The “Practical Theorist 12” focuses on the current state of marijuana in America. This document provides the reader a wide range of information on a variety of topics with findings based[Read More…]
Banking and Hemp-Related Businesses: Federal Guidance
The Financial Crimes Enforcement Network (FinCEN) just issued guidance to financial institutions doing business with hemp-related businesses. “Hemp” is a part of the Cannabis Sativa L. family that contains no more than .3 percent potency level of Delta-9 tetrahydrocannabinol (THC). Hemp was removed from the controlled substances list and reclassified[Read More…]
Legalization of Recreational Marijuana & Increased Traffic Fatality Rates
Released in the June 22, 2020 version of JAMA Internal Medicine (doi:10.1001/jamainternmed.2020.1769 ) comes research from Kamer (et.al) that examines the fatal motor vehicle collision rates in the original four states that legalized marijuana for “recreational” use. Three of the four states did record increases in their fatal collision rates post[Read More…]
High-Potency THC Products, Is the Bang Worth the Bucks?
The June 10, 2020 edition of the JAMA Psychiatry released emerging research from the University of Colorado (Boulder) into the effects of high and low potency THC with respect for both intoxication and impairment. This study looked at 121 participants who were dosed with raw marijuana flower (THC potency of[Read More…]
Impact of Recreational Cannabis Legalization In Michigan: A Baseline Report
The Injury Prevention Center (IPC), at the prestigious University of Michigan, is one of only nine such research centers in the United States that is funded by the Centers for Disease Control (CDC). The focus of the IPC is on the prevention and reduction of injuries by means of a[Read More…]
Retail Purchases of Marijuana Products – A Consumer Awareness Bulletin
When purchasing retail marijuana-based products, the consumer should be aware of the potential impacts of that choice, both financially and possibly to their own health. From reported adverse health effects stemming from use of high potency products to unsupported claims of medical benefits, this bulletin gives a broad overview of[Read More…]
High Potency Marijuana Usage: Increased Odds of Addiction and Anxiety Disorders in Frequent Users
Researchers in the United Kingdom have just released the findings of a longitudinal study on the relationship of high potency marijuana usage and its impacts on mental health outcomes as well as addiction. In this study of 1,087 participants who used high potency marijuana, researchers found that the respondents had[Read More…]